| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/29/2010 | CA2750457A1 New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative |
| 07/29/2010 | CA2750450A1 Novel indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use |
| 07/29/2010 | CA2750449A1 New adenosine receptor ligands and uses thereof |
| 07/29/2010 | CA2750447A1 N-oxides of diazabicyclononyl pyrimidine derivatives and their medical use |
| 07/29/2010 | CA2750400A1 Controlled release formulations with continuous efficacy |
| 07/29/2010 | CA2750340A1 Biofilm-removing antimicrobial compositions and uses thereof |
| 07/29/2010 | CA2750339A1 Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use |
| 07/29/2010 | CA2750265A1 Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease |
| 07/29/2010 | CA2750106A1 Poly (adp-ribose) polymerase (parp) inhibitors |
| 07/29/2010 | CA2750047A1 Novel bicyclic antibiotics |
| 07/29/2010 | CA2750044A1 Phd2 inhibition for blood vessel normalization, and uses thereof |
| 07/29/2010 | CA2750028A1 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical |
| 07/29/2010 | CA2750003A1 Controlled release systems from polymer blends |
| 07/29/2010 | CA2749993A1 Continuous double emulsion process for making microparticles |
| 07/29/2010 | CA2749981A1 Process for isolating tigecycline and tigecycline made therefrom |
| 07/29/2010 | CA2749970A1 Novel heterocyclic compounds as metap-2 inhibitors |
| 07/29/2010 | CA2749957A1 Solid pharmaceutical composition comprising amlodipine and losartan |
| 07/29/2010 | CA2749955A1 Solid pharmaceutical composition comprising amlodipine and losartan with improved stability |
| 07/29/2010 | CA2749931A1 Use of pterosin compounds for treating diabetes and obesity |
| 07/29/2010 | CA2749930A1 Bridged and fused heterocyclic antidiabetic compounds |
| 07/29/2010 | CA2749903A1 Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
| 07/29/2010 | CA2749891A1 Bridged and fused antidiabetic compounds |
| 07/29/2010 | CA2749853A1 Arginase inhibitors and methods of use |
| 07/29/2010 | CA2749700A1 Benzodiazepin-2-on derivatives |
| 07/29/2010 | CA2749663A1 Pentafluorosulpholane-containing antidiabetic compounds |
| 07/29/2010 | CA2749646A1 Delayed-release glucocorticoid treatment of asthma |
| 07/29/2010 | CA2749529A1 Quinazolinone derivatives useful as vanilloid antagonists |
| 07/29/2010 | CA2749217A1 Compositions and methods for inhibition of the jak pathway |
| 07/29/2010 | CA2749123A1 Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| 07/29/2010 | CA2749120A1 Improved vaccines for human papilloma virus and methods for using the same |
| 07/29/2010 | CA2749055A1 Antiviral agents |
| 07/29/2010 | CA2748957A1 Spiroindolinone derivative prodrugs |
| 07/29/2010 | CA2748896A1 Pharmaceutical composition comprising aleglitazar |
| 07/29/2010 | CA2748895A1 Pharmaceutical compositions with superior product performance and patient compliance |
| 07/29/2010 | CA2748864A1 Amino-heterocyclic compounds used as pde9 inhibitors |
| 07/29/2010 | CA2748587A1 Substituted pyrazinone amides |
| 07/29/2010 | CA2748464A1 Abuse resistant melt extruded formulation having reduced alcohol interaction |
| 07/29/2010 | CA2748400A1 Combinations comprising methotrexate and dhodh inhibitors |
| 07/29/2010 | CA2747801A1 N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity |
| 07/29/2010 | CA2747753A1 Nutritional supplements for 50+ individuals for improving vitality, immunity, eye and bone health |
| 07/29/2010 | CA2747251A1 Methods for treating acute myocardial infarctions and associated disorders |
| 07/29/2010 | CA2746902A1 A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without thenegative side effects of a mega dose nutritional supplement |
| 07/29/2010 | CA2746832A1 Phosphate management with small molecules |
| 07/29/2010 | CA2746821A1 Animal feed additive and animal feed comprising alkyl esters of medium chain fatty acids, and their use in animal feed |
| 07/28/2010 | EP2210956A2 Method to inhibit cell growth using oligonucleotides |
| 07/28/2010 | EP2210945A2 Neisseria meningitidis antigens |
| 07/28/2010 | EP2210893A1 Polymorphous forms of rifaximin as antibiotics |
| 07/28/2010 | EP2210892A2 Neurologically-active compounds |
| 07/28/2010 | EP2210891A1 New adenosine receptor ligands and uses thereof |
| 07/28/2010 | EP2210890A1 Oxadiazole derivatives as S1P1 receptor agonists |
| 07/28/2010 | EP2210889A1 Process for producing pyrimidine compound |
| 07/28/2010 | EP2210888A2 Stable micronized candesartan cilexetil and methods for preparing thereof |
| 07/28/2010 | EP2210887A1 Bis resorcinyl triazine derivatives as protecting agents against UV radiation |
| 07/28/2010 | EP2210886A1 Pyrimidyl indoline compound |
| 07/28/2010 | EP2210885A1 Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| 07/28/2010 | EP2210880A1 Benzoxazinone derivative |
| 07/28/2010 | EP2210878A1 Therapeutic agent for trpv1-mediated disease |
| 07/28/2010 | EP2210876A1 Heterocyclic compound |
| 07/28/2010 | EP2210872A1 New crystalline form III of agometalin, the process for its preparation and pharmaceutical compositions containing it |
| 07/28/2010 | EP2210643A2 Combinations comprising epothilones and pharmaceutical uses thereof |
| 07/28/2010 | EP2210615A1 Combinations comprising methotrexate and DHODH inhibitors |
| 07/28/2010 | EP2210614A1 Combinations comprising antimuscarinic agents and PDE4 inhibitors |
| 07/28/2010 | EP2210613A1 Combinations comprising antimuscarinic agents and PDE4 inhibitors |
| 07/28/2010 | EP2210607A1 N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| 07/28/2010 | EP2210606A2 Methods Of Using And Compositions Comprising Immunomodulatory Compounds For The Treatment And Management Of Myeloproliferative Diseases |
| 07/28/2010 | EP2210605A1 Once daily dosage forms of trospium |
| 07/28/2010 | EP2210604A1 Pharmaceutical compositions combining a nonsteroidal anti-inflammatory agent and a xanthine oxidase inhibiting agent, which can be used to control and treat gout, gouty arthritis and related diseases |
| 07/28/2010 | EP2210603A1 Pharmaceutical composition for inhibiting the accumulation of amyloid- b protein |
| 07/28/2010 | EP2210602A1 Compositions for the treatment of symptoms associated with respiratory inflammations |
| 07/28/2010 | EP2210601A1 Anti-fatigue agent comprising amino acid composition |
| 07/28/2010 | EP2210600A1 Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine |
| 07/28/2010 | EP2210599A1 Lidocaine tape preparation |
| 07/28/2010 | EP2210598A2 Anticonvulsant amino acids for the treatment of pain |
| 07/28/2010 | EP2210597A2 Bacterial virulence modifying agents |
| 07/28/2010 | EP2210596A1 Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof |
| 07/28/2010 | EP2210593A2 Tablettable formulations of vitamin A and derivatives thereof |
| 07/28/2010 | EP2210592A2 Stabilized Freeze-dried Formulation for Cephalosporin Derivatives |
| 07/28/2010 | EP2210590A1 Drug delivery system for use in the treatment of vascular and vessel-related pathologies |
| 07/28/2010 | EP2210587A1 Production process for NSAID-containing lozenges, their compositions, their medicinal use |
| 07/28/2010 | EP2210585A1 SPRM pharmaceutical compositions methods of treatment using them |
| 07/28/2010 | EP2210505A1 Composition comprising caftaric acid and/or derivatives thereof |
| 07/28/2010 | EP2210504A1 Composition comprising chicoric acid and/or derivatives thereof |
| 07/28/2010 | EP2209895A2 Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo |
| 07/28/2010 | EP2209810A1 Viral therapeutic |
| 07/28/2010 | EP2209801A2 Manufacture, compositions and uses of coagulationfactor viia modulator |
| 07/28/2010 | EP2209795A1 Aminooxime derivatives of 2- and/or 4-substituted androstanes and androstenes as medicaments for cardiovascular disorders |
| 07/28/2010 | EP2209794A1 Alpha-amylase inhibitors: the montbretins and uses thereof |
| 07/28/2010 | EP2209791A1 Heterocyclic derivatives |
| 07/28/2010 | EP2209790A2 Equilibrative nucleoside transporter ent1 inhibitors |
| 07/28/2010 | EP2209789A1 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
| 07/28/2010 | EP2209786A1 Pyrimidine substituted purine derivatives |
| 07/28/2010 | EP2209785A1 2-morpholinylpurines as inhibitors of pi3k |
| 07/28/2010 | EP2209782A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use |
| 07/28/2010 | EP2209780A2 Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof |
| 07/28/2010 | EP2209779A1 Heterocyclic urea and thiourea derivatives and methods of use thereof |
| 07/28/2010 | EP2209778A1 Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
| 07/28/2010 | EP2209777A2 Thiazol derivatives for treating cancer |
| 07/28/2010 | EP2209776A1 Aminoacyl prodrugs as an active pharmaceutical ingredient for thromboembolic disorder |
| 07/28/2010 | EP2209775A1 Heterobicyclic compounds as histamine h4-receptor antagonists |
| 07/28/2010 | EP2209774A1 Pyrimidinedione derivatives |